FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123148531> ?p ?o ?g. }

• W2123148531 endingPage "e2975" @default.
• W2123148531 startingPage "e2975" @default.
• W2123148531 abstract "Background Treatment and morbidity control of schistosomiasis relies on a single drug, praziquantel. Hence, there is a pressing need to develop additional therapeutics against schistosomiasis. The antimalarial drug mefloquine shows antischistosomal activity in animal models and clinical trials, which calls for further investigations. Methodology We comparatively assessed the efficacy and tolerability of the following treatments against Schistosoma haematobium in school-aged children in Côte d'Ivoire: (i) praziquantel (40 mg/kg; standard treatment); (ii) mefloquine (25 mg/kg) combined with praziquantel (40 mg/kg); and (iii) mefloquine-artesunate (3× (100 mg artesunate +250 mg mefloquine)) combined with praziquantel (40 mg/kg) (treatments administered on subsequent days). Two urine samples were collected before, and on days 21–22 and 78–79 after the first dosing. Principal Findings Sixty-one children were present on all examination time points and had complete datasets. No difference in efficacy was observed between the three treatment groups on either follow-up. On the 21–22 day posttreatment follow-up, based on available case analysis, cure rates of 33% (95% confidence interval (CI) 11–55%), 29% (95% CI 8–50%), and 26% (95% CI 5–48%) were observed for praziquantel, mefloquine-artesunate-praziquantel, and mefloquine-praziquantel, respectively. The corresponding egg reduction rates were 94% and above. On the second follow-up, observed cure rates ranged from 19% (praziquantel) to 33% (mefloquine-artesunate-praziquantel), and egg reduction rates were above 90%. Praziquantel monotherapy was the best tolerated treatment. In the mefloquine-artesunate-praziquantel group, adverse events were reported by 91% of the participants, and in the mefloquine-praziquantel group, 95% experienced adverse events. With the exception of abdominal pain at moderate severity, adverse events were mild. Conclusions/Significance The addition of mefloquine or mefloquine-artesunate does not increase the efficacy of praziquantel against chronic S. haematobium infection. Additional studies are necessary to elucidate the effect of the combinations against acute schistosomiasis." @default.
• W2123148531 created "2016-06-24" @default.
• W2123148531 creator A5003934187 @default.
• W2123148531 creator A5020930943 @default.
• W2123148531 creator A5028290963 @default.
• W2123148531 creator A5033452459 @default.
• W2123148531 creator A5038182993 @default.
• W2123148531 creator A5058826264 @default.
• W2123148531 creator A5067569019 @default.
• W2123148531 date "2014-07-17" @default.
• W2123148531 modified "2023-10-17" @default.
• W2123148531 title "Praziquantel, Mefloquine-Praziquantel, and Mefloquine-Artesunate-Praziquantel against Schistosoma haematobium: A Randomized, Exploratory, Open-Label Trial" @default.
• W2123148531 cites W1485932791 @default.
• W2123148531 cites W1996354214 @default.
• W2123148531 cites W2006452977 @default.
• W2123148531 cites W2012655535 @default.
• W2123148531 cites W2031131325 @default.
• W2123148531 cites W2033216955 @default.
• W2123148531 cites W2051840067 @default.
• W2123148531 cites W2066835202 @default.
• W2123148531 cites W2067454999 @default.
• W2123148531 cites W2082479593 @default.
• W2123148531 cites W2088530291 @default.
• W2123148531 cites W2095248243 @default.
• W2123148531 cites W2097950056 @default.
• W2123148531 cites W2105625891 @default.
• W2123148531 cites W2113143110 @default.
• W2123148531 cites W2115323998 @default.
• W2123148531 cites W2116106523 @default.
• W2123148531 cites W2122395806 @default.
• W2123148531 cites W2129025906 @default.
• W2123148531 cites W2132621607 @default.
• W2123148531 cites W2148036897 @default.
• W2123148531 cites W2160943186 @default.
• W2123148531 cites W2161002247 @default.
• W2123148531 cites W2161980749 @default.
• W2123148531 cites W2167306484 @default.
• W2123148531 cites W2168434488 @default.
• W2123148531 cites W2168714828 @default.
• W2123148531 cites W4253043716 @default.
• W2123148531 doi "https://doi.org/10.1371/journal.pntd.0002975" @default.
• W2123148531 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4102459" @default.
• W2123148531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25033291" @default.
• W2123148531 hasPublicationYear "2014" @default.
• W2123148531 type Work @default.
• W2123148531 sameAs 2123148531 @default.
• W2123148531 citedByCount "38" @default.
• W2123148531 countsByYear W21231485312014 @default.
• W2123148531 countsByYear W21231485312015 @default.
• W2123148531 countsByYear W21231485312016 @default.
• W2123148531 countsByYear W21231485312017 @default.
• W2123148531 countsByYear W21231485312018 @default.
• W2123148531 countsByYear W21231485312019 @default.
• W2123148531 countsByYear W21231485312020 @default.
• W2123148531 countsByYear W21231485312021 @default.
• W2123148531 countsByYear W21231485312022 @default.
• W2123148531 countsByYear W21231485312023 @default.
• W2123148531 crossrefType "journal-article" @default.
• W2123148531 hasAuthorship W2123148531A5003934187 @default.
• W2123148531 hasAuthorship W2123148531A5020930943 @default.
• W2123148531 hasAuthorship W2123148531A5028290963 @default.
• W2123148531 hasAuthorship W2123148531A5033452459 @default.
• W2123148531 hasAuthorship W2123148531A5038182993 @default.
• W2123148531 hasAuthorship W2123148531A5058826264 @default.
• W2123148531 hasAuthorship W2123148531A5067569019 @default.
• W2123148531 hasBestOaLocation W21231485311 @default.
• W2123148531 hasConcept C126322002 @default.
• W2123148531 hasConcept C165901193 @default.
• W2123148531 hasConcept C197934379 @default.
• W2123148531 hasConcept C203014093 @default.
• W2123148531 hasConcept C2776225656 @default.
• W2123148531 hasConcept C2776908094 @default.
• W2123148531 hasConcept C2777199930 @default.
• W2123148531 hasConcept C2777445151 @default.
• W2123148531 hasConcept C2778048844 @default.
• W2123148531 hasConcept C2778059366 @default.
• W2123148531 hasConcept C2778371730 @default.
• W2123148531 hasConcept C2778375690 @default.
• W2123148531 hasConcept C2779744950 @default.
• W2123148531 hasConcept C42972112 @default.
• W2123148531 hasConcept C71924100 @default.
• W2123148531 hasConcept C98274493 @default.
• W2123148531 hasConceptScore W2123148531C126322002 @default.
• W2123148531 hasConceptScore W2123148531C165901193 @default.
• W2123148531 hasConceptScore W2123148531C197934379 @default.
• W2123148531 hasConceptScore W2123148531C203014093 @default.
• W2123148531 hasConceptScore W2123148531C2776225656 @default.
• W2123148531 hasConceptScore W2123148531C2776908094 @default.
• W2123148531 hasConceptScore W2123148531C2777199930 @default.
• W2123148531 hasConceptScore W2123148531C2777445151 @default.
• W2123148531 hasConceptScore W2123148531C2778048844 @default.
• W2123148531 hasConceptScore W2123148531C2778059366 @default.
• W2123148531 hasConceptScore W2123148531C2778371730 @default.
• W2123148531 hasConceptScore W2123148531C2778375690 @default.
• W2123148531 hasConceptScore W2123148531C2779744950 @default.
• W2123148531 hasConceptScore W2123148531C42972112 @default.
• W2123148531 hasConceptScore W2123148531C71924100 @default.
• W2123148531 hasConceptScore W2123148531C98274493 @default.

• next